Filters: Keyword is Antibodies, Monoclonal, Humanized [Clear All Filters]
"Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model." The Journal of allergy and clinical immunology 120, no. 5 (2007): 1146-52. Abstract
